New Approach to Cancer Immunotherapy
Author Information
Author(s): Feng Bing, Tang Li
Primary Institution: École Polytechnique Fédérale de Lausanne (EPFL)
Hypothesis
Type 2 immune factors could alleviate T-cell exhaustion and enhance their functionality against solid tumors.
Conclusion
Type 2 immunity, particularly the cytokine Fc–IL‐4, can enhance the effectiveness of current cancer immunotherapies.
Supporting Evidence
- Type 2 high CAR-T cells showed a higher proportion in patients who were cured.
- Fc–IL‐4 enhanced the cytotoxicity and functionality of exhausted CD8+ T cells.
- Combination therapies with Fc–IL‐4 showed robust antitumor efficacy in multiple models.
Takeaway
This study shows that a special part of the immune system can help fight cancer better by working together with other immune responses.
Methodology
The study involved a comprehensive single-cell multi-omics analysis of CAR-T cells from pediatric patients and preclinical experiments with engineered fusion proteins.
Participant Demographics
Pediatric patients with B-acute lymphoblastic leukaemia and healthy donors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website